Eligible patients ( aged 18-75 years ; Mayo Clinic Score [ MCS ] of 5 of higher [ or 6 in USA ] ; and disease extending 25 cm or more from anal verge ) were randomised ( 1:1:1 ) to one of two dose levels of subcutaneous etrolizumab ( 100 mg at weeks 0 , 4 , and 8 , with placebo at week 2 ; or 420 mg loading dose [ LD ] at week 0 followed by 300 mg at weeks 2 , 4 , and 8 ) , or matching placebo .